Rock Springs Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,734,037
| Closed | -$3.83M | – | 128 |
|
|
2023
Q2 | $3.83M | Hold |
1,734,037
| – | – | 0.09% | 93 |
|
|
2023
Q1 | $4.4M | Hold |
1,734,037
| – | – | 0.11% | 93 |
|
|
2022
Q4 | $3.24M | Hold |
1,734,037
| – | – | 0.08% | 96 |
|
|
2022
Q3 | $4.46M | Hold |
1,734,037
| – | – | 0.12% | 96 |
|
|
2022
Q2 | $3.35M | Buy |
1,734,037
+7,400
| +0.4% | +$16.1K | 0.1% | 103 |
|
|
2022
Q1 | $5.13M | Buy |
1,726,637
+29,532
| +2% | +$111K | 0.13% | 103 |
|
|
2021
Q4 | $7.62M | Buy |
1,697,105
+32,091
| +2% | +$152K | 0.18% | 102 |
|
|
2021
Q3 | $8.09M | Buy |
1,665,014
+10,300
| +0.6% | +$56.8K | 0.17% | 115 |
|
|
2021
Q2 | $11.3M | Sell |
1,654,714
-30,000
| -2% | -$243K | 0.22% | 106 |
|
|
2021
Q1 | $11.9M | Buy |
1,684,714
+4,100
| +0.2% | +$29.5K | 0.26% | 100 |
|
|
2020
Q4 | $10.5M | Buy |
1,680,614
+7,200
| +0.4% | +$42.4K | 0.22% | 113 |
|
|
2020
Q3 | $9.05M | Buy |
1,673,414
+18,250
| +1% | +$90.4K | 0.23% | 106 |
|
|
2020
Q2 | $8.64M | Buy |
1,655,164
+128,854
| +8% | +$572K | 0.24% | 108 |
|
|
2020
Q1 | $4.81M | Buy |
1,526,310
+1,151,310
| +307% | +$4.25M | 0.2% | 101 |
|
|
2019
Q4 | $1.51M | Sell |
375,000
-75,000
| -17% | -$260K | 0.05% | 121 |
|
|
2019
Q3 | $1.94M | Hold |
450,000
| – | – | 0.08% | 126 |
|
|
2019
Q2 | $1.8M | Hold |
450,000
| – | – | 0.07% | 124 |
|
|
2019
Q1 | $2.41M | Hold |
450,000
| – | – | 0.09% | 118 |
|
|
2018
Q4 | $2.31M | Hold |
450,000
| – | – | 0.11% | 121 |
|
|
2018
Q3 | $4.37M | Hold |
450,000
| – | – | 0.16% | 123 |
|
|
2018
Q2 | $4.59M | Hold |
450,000
| – | – | 0.18% | 120 |
|
|
2018
Q1 | $5.85M | Hold |
450,000
| – | – | 0.25% | 109 |
|
|
2017
Q4 | $8.05M | Hold |
450,000
| – | – | 0.37% | 84 |
|
|
2017
Q3 | $11.3M | Sell |
450,000
-150,000
| -25% | -$3.49M | 0.52% | 65 |
|
|
2017
Q2 | $14.5M | Buy |
600,000
+74,500
| +14% | +$1.65M | 0.73% | 48 |
|
|
2017
Q1 | $10.1M | Hold |
525,500
| – | – | 0.58% | 56 |
|
|
2016
Q4 | $8.09M | Buy |
525,500
+23,000
| +5% | +$299K | 0.54% | 57 |
|
|
2016
Q3 | $6.54M | Buy |
502,500
+84,000
| +20% | +$1.11M | 0.41% | 72 |
|
|
2016
Q2 | $5.82M | Buy |
418,500
+195,500
| +88% | +$2.88M | 0.43% | 77 |
|
|
2016
Q1 | $3.38M | Buy |
223,000
+192,173
| +623% | +$2.94M | 0.28% | 97 |
|
|
2015
Q4 | $585K | Buy |
+30,827
| New | +$588K | 0.04% | 119 |
|
Rock Springs Capital Management's PRTK Position: Q3 2023 in Review
Rock Springs Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 1,734,037 shares — an estimated $3.83M sold.
Rock Springs Capital Management first reported a position in PRTK in Q4 2015 and held it in 31 quarters. The position peaked at $14.5M in Q2 2017. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Rock Springs Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Rock Springs Capital Management sold 1,734,037 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $3.83M.
- Rock Springs Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2015 and held it in 31 quarters.
- Rock Springs Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $14.5M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Rock Springs Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.